Moslem Abolhassani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Moslem Abolhassani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Fatemeh Yousefi
Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Gholamreza Asadikaram
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Saeid Karamouzian
Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. ; Afzal Research Institute (NGO), Kerman, Iran
2 shared publications - Vahid Moazed
Hematology and Oncology, Hematology Research Center, Kerman University of Medical Science, Kerman, Iran
2 shared publications - Erfan Sadeghi
Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Hamed Akbari
Cardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
1 shared publication
Latest Publications
- Open Access
- 9 February 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-12
Organochlorine Pesticides and Epigenetic Alterations in Brain Cancer
Epigenetic alterations have emerged as critical factors in the pathogenesis of brain cancer, particularly gliomas. This article explores the impact of organochlorine pesticides (OCPs) on the hypermethylation of key tumor suppressor genes, and some histone modifications in primary brain tumor (PBT) patients. This study involved 73 patients diagnosed with PBT and 15 non-cancerous brain tissue samples as contol. DNA extracted from tumor specimens was used to evaluate the methylation status of tumor suppressor genes, P16 and RRP22, using the methylation-specific PCR (MSP) technique and four histone marks (H4K16ac, H3K9ac, H4K20me3, and H3k4me2) to investigate by western blotting. The results of MSP revealed the methylation of RRP22 and P16 promoter regions and western blot analysis demonstrated significantly low levels of H3K9ac, H4K20me3, and H3K4me2 in PBT patients in comparison with the controls. The results of regression analysis revealed direct and significant correlations between serum OCPs concentration and methylation of RRP22 and P16. Furthermore, a direct and significant association was observed between hypomethylation of histones H3K4 and H4K20, as well as hypoacetylation of H3K9, with OCPs levels. This study revealed that epigenetic modifications play a significant role in the development of brain tumors, with OCPs identified as key contributors to these changes. Our research indicated that in patients with PBT, hypermethylation of the RRP22 and P16 gene and histone modifications correlates directly and significantly with the levels of OCPs found in their serum. Graphical Abstract Organochlorine pesticides exposure and epigenetic modifications in brain cancer: This study reveals that pesticide exposure may significantly induce the epigenetic modifications and by this way, participate in primary brain cancer development.
- 9 February 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-12
Open AccessOrganochlorine Pesticides and Epigenetic Alterations in Brain Cancer
Epigenetic alterations have emerged as critical factors in the pathogenesis of brain cancer, particularly gliomas. This article explores the impact of organochlorine pesticides (OCPs) on the hypermethylation of key tumor suppressor genes, and some histone modifications in primary brain tumor (PBT) patients. This study involved 73 patients diagnosed with PBT and 15 non-cancerous brain tissue samples as contol. DNA extracted from tumor specimens was used to evaluate the methylation status of tumor suppressor genes, P16 and RRP22, using the methylation-specific PCR (MSP) technique and four histone marks (H4K16ac, H3K9ac, H4K20me3, and H3k4me2) to investigate by western blotting. The results of MSP revealed the methylation of RRP22 and P16 promoter regions and western blot analysis demonstrated significantly low levels of H3K9ac, H4K20me3, and H3K4me2 in PBT patients in comparison with the controls. The results of regression analysis revealed direct and significant correlations between serum OCPs concentration and methylation of RRP22 and P16. Furthermore, a direct and significant association was observed between hypomethylation of histones H3K4 and H4K20, as well as hypoacetylation of H3K9, with OCPs levels. This study revealed that epigenetic modifications play a significant role in the development of brain tumors, with OCPs identified as key contributors to these changes. Our research indicated that in patients with PBT, hypermethylation of the RRP22 and P16 gene and histone modifications correlates directly and significantly with the levels of OCPs found in their serum. Graphical Abstract Organochlorine pesticides exposure and epigenetic modifications in brain cancer: This study reveals that pesticide exposure may significantly induce the epigenetic modifications and by this way, participate in primary brain cancer development.
- Open Access
- 1 April 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (3) , 324-331
Can Estradiol and Ghrelin Play a Protective Role in Epithelial Ovarian Cancer Incidence in Postmenopausal Women?
- 1 April 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (3) , 324-331
Open AccessCan Estradiol and Ghrelin Play a Protective Role in Epithelial Ovarian Cancer Incidence in Postmenopausal Women?
- 1 January 2021
- Published by Maad Rayan Publishing Company in Environmental Health Engineering and Management
- Vol. 8 (1) , 47-53
MGMT methylation alterations in brain cancer following organochlorine pesticides exposure
Background: Alterations in the methylation levels of tumor suppressor genes are considered as one of the essential aspects of malignancies. The present study explored the association of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, as a tumor suppressor, with some organochlorine pesticides (OCPs) in primary brain tumor (PBT) patients. Methods: The present study was conducted on a total of 73 PBT patients. The patients’ serum was analyzed using gas chromatography for seven OCP derivatives. The methylation-specific PCR (MSP) method was also used to determine the methylation status of the MGMT promoter. Results: The current findings demonstrated that the methylation of MGMT promoter occurred in 22 out of 34 glioma cases (64%), but in only one out of 35 meningioma cases. No MGMT promoter methylation was observed in other PBT, hemangioma, and anaplastic medulloblastoma stages. Besides, there were significant associations between MGMT methylation and γ-HCH (odds ratio [OR]: 1.50; 95% CI: 1.03- 2.40, P=0.04), 4,4DDE (OR: 1.44; 95% CI: 1.01- 2.05, P=0.02), 2,4 DDT (OR: 1.23; CI: 1.04- 1.45, P=0.03), and 4,4DDT (OR: 1.46; CI: 1.23- 2.15, P=0.02) in glioma patients. Conclusion: The results of the study suggested that the hypermethylation of the MGMT promoter in glioma patients is associated with increased OCPs in their serum, especially γ- HCH, 4,4DDE, 2,4DDT, and 4,4DDT. Moreover, it may lead to the hypermethylation of the MGMT promoter gene. Hence, it can be concluded that exposure to OCPs may potentially induce glioma.
- 1 January 2021
- Published by Maad Rayan Publishing Company in Environmental Health Engineering and Management
- Vol. 8 (1) , 47-53
MGMT methylation alterations in brain cancer following organochlorine pesticides exposure
Background: Alterations in the methylation levels of tumor suppressor genes are considered as one of the essential aspects of malignancies. The present study explored the association of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, as a tumor suppressor, with some organochlorine pesticides (OCPs) in primary brain tumor (PBT) patients. Methods: The present study was conducted on a total of 73 PBT patients. The patients’ serum was analyzed using gas chromatography for seven OCP derivatives. The methylation-specific PCR (MSP) method was also used to determine the methylation status of the MGMT promoter. Results: The current findings demonstrated that the methylation of MGMT promoter occurred in 22 out of 34 glioma cases (64%), but in only one out of 35 meningioma cases. No MGMT promoter methylation was observed in other PBT, hemangioma, and anaplastic medulloblastoma stages. Besides, there were significant associations between MGMT methylation and γ-HCH (odds ratio [OR]: 1.50; 95% CI: 1.03- 2.40, P=0.04), 4,4DDE (OR: 1.44; 95% CI: 1.01- 2.05, P=0.02), 2,4 DDT (OR: 1.23; CI: 1.04- 1.45, P=0.03), and 4,4DDT (OR: 1.46; CI: 1.23- 2.15, P=0.02) in glioma patients. Conclusion: The results of the study suggested that the hypermethylation of the MGMT promoter in glioma patients is associated with increased OCPs in their serum, especially γ- HCH, 4,4DDE, 2,4DDT, and 4,4DDT. Moreover, it may lead to the hypermethylation of the MGMT promoter gene. Hence, it can be concluded that exposure to OCPs may potentially induce glioma.